ABPath - American Board of Pathology Laboratory Management Questions and Answers 1 — Questions and Answers
Question 1: A new molecular diagnostics section is being established, which will perform high-complexity testing. According to CLIA '88 regulations, which of the following individuals meets the minimum qualifications to serve as the Technical Supervisor for this section?
- An individual with an associate's degree in medical laboratory technology and 4 years of experience in high-complexity testing.
- An individual with a bachelor's degree in clinical laboratory science and 2 years of experience in high-complexity testing. (Correct answer)
- A physician with a license to practice medicine and 1 year of experience overseeing a moderate complexity laboratory.
- An individual with a master's degree in biology and 6 months of training in the specific high-complexity assays being performed.
Correct answer: An individual with a bachelor's degree in clinical laboratory science and 2 years of experience in high-complexity testing.
CLIA '88 specifies several pathways to qualify as a Technical Supervisor for high-complexity testing. One of the most common pathways requires an individual to have earned a bachelor's degree in a relevant science (such as clinical laboratory science or medical technology) and have at least 2 years of pertinent laboratory experience in high-complexity testing. The other options are incorrect because they lack the required degree level, sufficient duration of experience, or experience specifically in high-complexity testing.
Question 2: A chemistry analyzer's daily quality control for creatinine has a mean of 1.0 mg/dL and a standard deviation (SD) of 0.05 mg/dL. The results for the last two consecutive runs of the same control level were 1.11 mg/dL and 1.12 mg/dL. This pattern represents a violation of which Westgard rule?
- 1_3s
- R_4s
- 4_1s
- 2_2s (Correct answer)
Correct answer: 2_2s
The 2_2s Westgard rule is violated when two consecutive quality control points for the same level fall outside the same +2 SD or -2 SD limit. In this scenario, the +2 SD limit is 1.10 mg/dL (1.0 + 2*0.05). Both QC results (1.11 and 1.12 mg/dL) exceed this limit, indicating a systematic error that requires investigation.
Question 3: According to the Occupational Safety and Health Administration (OSHA) Laboratory Standard (29 CFR 1910.1450), which of the following is a required element of a laboratory's Chemical Hygiene Plan (CHP)?
- Criteria the employer will use to determine and implement control measures, such as engineering controls and personal protective equipment. (Correct answer)
- The specific brand and vendor for all personal protective equipment used in the laboratory.
- A list of all employees who have been exposed to hazardous chemicals in the past year.
- The fee schedule for medical consultations and examinations for employees with potential overexposure.
Correct answer: Criteria the employer will use to determine and implement control measures, such as engineering controls and personal protective equipment.
The OSHA Laboratory Standard (29 CFR 1910.1450) mandates that a laboratory's written Chemical Hygiene Plan (CHP) must include specific elements. A key required component is the establishment of criteria that the employer will use to determine and implement control measures to reduce employee exposure, including engineering controls, administrative controls, and personal protective equipment.
Question 4: A clinical laboratory is implementing a new, unmodified, FDA-approved assay. According to CLIA '88, which of the following sets of performance characteristics must the laboratory verify before using the test for patient reporting?
- Analytical sensitivity, analytical specificity, and linearity.
- Full method validation including interfering substance studies.
- Accuracy, precision, reportable range, and reference interval. (Correct answer)
- Only the manufacturer's stated reportable range and reference interval.
Correct answer: Accuracy, precision, reportable range, and reference interval.
For an unmodified, FDA-approved test, CLIA '88 requires the laboratory to *verify* the manufacturer's stated performance specifications. This verification process must include demonstrating performance for accuracy, precision, reportable range, and verifying that the manufacturer's reference interval is appropriate for the laboratory's patient population. A full, more extensive validation is required only for laboratory-developed tests or modified FDA-approved tests.
Question 5: A laboratory is considering purchasing a new instrument that has a fixed cost of $120,000. The variable cost per test (e.g., reagents, consumables) is $8, and the reimbursement per test is $20. Disregarding other fixed costs like labor and overhead, how many tests must be performed to reach the break-even point for the instrument?
- 6,000
- 15,000
- 5,000
- 10,000 (Correct answer)
Correct answer: 10,000
The break-even point in units is calculated by dividing the total fixed costs by the contribution margin per unit. First, calculate the contribution margin: Reimbursement ($20) - Variable Cost ($8) = $12 per test. Then, divide the fixed cost by the contribution margin: $120,000 / $12 = 10,000 tests.
Question 6: A laboratory fails a proficiency testing (PT) event for a CLIA-regulated analyte. This is the second consecutive PT event where the laboratory has demonstrated unsuccessful performance for this same analyte. According to CLIA regulations, what is the most significant and immediate required action?
- The laboratory director must attend remedial training.
- The laboratory is placed on probation and subject to an on-site inspection.
- The laboratory must immediately cease all patient testing for that specific analyte. (Correct answer)
- The laboratory must pay a monetary fine and submit a corrective action plan.
Correct answer: The laboratory must immediately cease all patient testing for that specific analyte.
Under CLIA '88, failing to achieve a satisfactory score on two consecutive or two out of three proficiency testing (PT) events for an analyte is defined as "unsuccessful performance." The primary and mandatory sanction for unsuccessful performance is the immediate cessation of all patient testing for that analyte. The laboratory cannot resume testing until the problem is corrected and satisfactory performance is demonstrated on two subsequent PT events.
ABPath - American Board of Pathology Laboratory Management Questions and Answers 1
A new molecular diagnostics section is being established, which will perform high-complexity testing.
According to CLIA '88 regulations, which of the following individuals meets the minimum qualifications to serve as the Technical Supervisor for this section?